PCORI Call for Proposals for HSII Implementation Projects
Patient-Centered Outcomes Research Institute
Association/Society
United States
Up to US $2,500,000
The PCORI Call for Proposals for HSII Implementation Projects invites innovative approaches to address barriers in healthcare settings. These projects should enhance practice change through active, multi-component strategies and include rigorous evaluations to measure implementation effectiveness. While developing tools to support these strategies is permitted, it should not be the main focus. Successful proposals will demonstrate their potential impact on healthcare outcomes and patient experiences.
Medical Education & Professional Training
Cardiovascular Diseases & Systems
Ollie Hinkle Heart Foundation: Technology Grant
Ollie Hinkle Heart Foundation
Private
United States
Unspecified amount
The Ollie Hinkle Heart Foundation's Technology Grant aims to improve pediatric heart care outcomes through innovative collaborations. By focusing on predictive technologies for early recognition, precision for personalized care, and preventive measures for quality of life, the foundation seeks to transform care for heart children and their families. Their mission emphasizes community support, education, and advocacy to ensure no family faces unmet needs alone, creating a legacy of love and courage in the heart community.
Cardiovascular Diseases & Systems
Children’s Health & Pediatrics
Medical Technology, Devices, and Equipment
Limited Competition PCORI Funding: Implementation Awards -- Cycle 3 2026
Patient-Centered Outcomes Research Institute
Association/Society
United States
Up to US $2,500,000
The Implementation Awards by PCORI aim to fund projects that translate patient-centered research into real-world practices. With budgets up to $2.5 million for implementation projects lasting up to 48 months, applicants must present a clear plan for broad evidence uptake. Additionally, those proposing implementation projects need an accepted Draft Final Research Report related to their original PCORI-funded research to qualify for funding.
Patient Care & Services
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
US Department of Health & Human Services: Food and Drug Administration (FDA)
Federal Government
American Samoa, Guam +4 more
Up to US $600,000
This funding opportunity aims to enhance the development of medical products in rare diseases through innovative natural history studies. By generating high-quality data, the FDA seeks to bridge critical knowledge gaps and eliminate barriers in rare disease research. The initiative focuses on diseases with unmet needs, fostering significant impacts for those affected and facilitating the development of effective therapeutic solutions.
Rare Diseases
Manufacturing Engineering
Pharmacology
+1 more
NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (360006)
US Department of Health & Human Services: Food and Drug Administration (FDA)
Federal Government
American Samoa, Guam +4 more
Up to US $200,000
The NARMS Cooperative Agreement Program aims to enhance antibiotic resistance surveillance in retail food specimens. Funded by the FDA, this initiative strengthens the National Antimicrobial Resistance Monitoring System established in 1996. By improving detection methods and expanding sampling sites, the program seeks to protect public health and align with NARMS objectives, ultimately combating the growing threat of antibiotic resistance in food commodities.
Drug-Resistant Bacteria
Epidemiology & Public Health
Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
US Department of Health & Human Services: Food and Drug Administration (FDA)
Federal Government
American Samoa, Guam +4 more
Up to US $900,000
The RFA-FD-23-001 funding opportunity aims to support clinical trials for orphan products targeting rare diseases. It focuses on evaluating the efficacy and safety of treatments to address unmet medical needs. By promoting innovative and collaborative trial designs, the FDA seeks to enhance the approval rates of effective therapies for rare conditions, ultimately benefiting patients and advancing drug development in this critical area.
Rare Diseases
Medical Ethics
Human Genome & Genetics